Study S000134

A PHASE 1, OPEN- LABEL STUDY TO EVALUATE THE MULTIPLE DOSE PHARMACOKINETICS OF DANUGLIPRON FOLLOWING ORAL ADMINISTRATION IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06568731
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 23
Start: 2024-08-23
Primary completion: 2024-12-18
Lead sponsor: Pfizer
Conditions: Obesity
Interventions: DRUG:Danuglipron
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: REGISTRY:NCT06568731

Registered primary outcomes

Steady-state area under the concentration-time profile from time zero to 24 hours (AUC24) for danuglipron [Predose to 24 hours post danuglipron administration]
Steady-state maximum observed concentration (Cmax) for danuglipron [Predose to 24 hours post danuglipron administration]
Steady-state time to reach maximum observed concentration (Tmax) for danuglipron [Predose to 24 hours post danuglipron administration]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.